TELA Bio, Inc.

TELA Bio, Inc. is a United States-based surgical reconstruction company focused on soft-tissue repair. According to its official website, the company provides "innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy." Its product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials, and the company emphasizes delivering advanced technologies with a strong economic value proposition so that surgeons and institutions can offer next-generation soft-tissue repair to more patients. The company's flagship platform is the OviTex Reinforced Tissue Matrix, used in hernia and abdominal wall reconstruction. OviTex is composed of ovine forestomach (OFM), which provides a functional extracellular matrix (ECM), combined with a proprietary polymer embroidery. This design is positioned as an alternative to permanent and resorbable synthetic mesh, reducing the amount of plastic in the body while enhancing strength and durability at the repair site. A related line, OviTex PRS Reinforced Tissue Matrix, is designed specifically for plastic and reconstructive surgery and is described as the only biologic reinforced with interwoven polymer suture, with multiple resorption, stretch and shape offerings. TELA Bio is headquartered in Malvern, Pennsylvania, in the United States, and operates in the medical technology sector. Its leadership team is drawn from the MedTech industry, with Heather C. Getz serving as Chief Executive Officer, Jeffrey Blizard as President, Paul Talmo as Chief Science and Innovation Officer, and Howard N. Langstein, MD, FACS, as Chief Medical Officer, among other senior executives. The company also has a European presence through a Senior Vice President for TELA Bio Europe. As a commercial-stage medical device company, TELA Bio competes in the soft-tissue reconstruction and surgical mesh market, where it differentiates through its biologic-plus-polymer reinforced tissue matrix approach and its stated focus on value for surgeons and healthcare institutions.

TELA Bio, Inc. is a surgical reconstruction company headquartered in Malvern, Pennsylvania, in the United States. The company was established to address gaps in soft-tissue surgical innovation, with a stated mission of improving patient outcomes through solutions that preserve and restore the patient's own anatomy while minimizing long-term exposure to permanent synthetic materials. From the outset, TELA Bio has focused on soft-tissue repair, particularly hernia and abdominal wall reconstruction. Its flagship product, the OviTex Reinforced Tissue Matrix, combines ovine forestomach (OFM) — a functional extracellular matrix (ECM) — with a proprietary polymer embroidery. This hybrid design is positioned as an alternative to both permanent and resorbable synthetic mesh, reducing the amount of plastic implanted in the body while enhancing strength and durability at the repair site. The company later extended the platform to plastic and reconstructive surgery with OviTex PRS, described as the only biologic reinforced with interwoven polymer suture and offered in multiple resorption, stretch and shape configurations. TELA Bio has built a leadership team with extensive MedTech experience. Heather C. Getz serves as Chief Executive Officer, Jeffrey Blizard as President, Paul Talmo as Chief Science and Innovation Officer, and Howard N. Langstein, MD, FACS, as Chief Medical Officer. The company also maintains a European presence, with a Senior Vice President overseeing TELA Bio Europe. Its board of directors includes Joseph Capper as Chairman, along with Guido Neels, Guy Nohra, Paul Thomas, Bill Plovanic, Betty Jo Rocchio, and CEO Heather C. Getz. As a commercial-stage medical device company, TELA Bio markets its products to surgeons and healthcare institutions, emphasizing both clinical innovation and economic value. The company is publicly traded, and its continued growth centers on expanding the OviTex portfolio and advancing next-generation soft-tissue repair technologies.

Developer of soft-tissue reconstruction solutions that preserve and restore the patient's own anatomy while minimizing long-term exposure to permanent synthetic materials, delivered with a strong economic value proposition.

• OviTex Reinforced Tissue Matrix

  Composed of ovine forestomach (OFM) providing a functional extracellular matrix (ECM) and a proprietary polymer embroidery; used for hernia and abdominal wall reconstruction as an alternative to permanent and resorbable synthetic mesh.

• OviTex PRS Reinforced Tissue Matrix

  Described as the only biologic reinforced with interwoven polymer suture, designed specifically for plastic and reconstructive surgery, with multiple resorption, stretch and shape offerings.

1. 1TELA Bio | Surgical Reconstruction Companytelabio.com
2. 2About Us | TELA Biotelabio.com
3. 3TELA Bio, Inc. - Wikidatawikidata.org